Holen Sie sich die Stockscreener-App
88.43
1.18%
1.03
Handel nachbörslich:
90.19
1.76
+1.99%
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - The Motley Fool
Patient Square Capital LP Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Buybacks Report: Can Kymera Therapeutics Inc outperform under higher oil pricesGlobal Markets & Technical Pattern Based Buy Signals - baoquankhu1.vn
Analysis Recap: Why is AXTA stock going upJuly 2025 Spike Watch & Target Return Focused Picks - baoquankhu1.vn
Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises (KYMR) - Seeking Alpha
What makes Kymera Therapeutics Inc. stock attractive to growth fundsWeekly Investment Report & Momentum Based Trading Signals - mfd.ru
Is Kymera Therapeutics Inc. forming a bullish divergence2025 Risk Factors & Daily Market Momentum Tracking - mfd.ru
BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Kymera Therapeutics (KYMR) to Release Earnings on Thursday - Defense World
Kymera earnings up next as protein degrader rally faces catalyst test - Investing.com Nigeria
Kymera earnings up next as protein degrader rally faces catalyst test By Investing.com - Investing.com South Africa
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More - AOL.com
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: 41.75% Upside Potential with Robust Analyst Ratings - DirectorsTalk Interviews
Wellington Management Group LLP Reduces Stake in Kymera Therapeu - GuruFocus
Targeted Protein Degradation Market to hit US$ 4.53 Billion - openPR.com
Signal Recap: How sensitive is Kymera Therapeutics Inc to inflationJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
How sensitive is Kymera Therapeutics Inc. to inflationJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
How Kymera Therapeutics Inc. (KYMR) Affects Rotational Strategy Timing - Stock Traders Daily
Will Kymera Therapeutics Inc. face regulatory challenges2025 Geopolitical Influence & Fast Moving Stock Watchlists - mfd.ru
What is the long term forecast for Kymera Therapeutics Inc. stock2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Kymera Therapeutics Touts Once-Daily Oral “Biologics-Like” KT-621 at Guggenheim Conference - Yahoo Finance
Kymera Therapeutics discloses new STAT6 inhibitors - bioworld.com
What is Kymera Therapeutics Inc. s 5 year growth outlookMarket Sentiment Summary & Weekly Top Gainers Alerts - mfd.ru
What’s the outlook for Kymera Therapeutics Inc.’s sectorAnalyst Downgrade & Smart Investment Allocation Insights - mfd.ru
Kymera at Guggenheim Biotech Summit: Exploring Oral Drug Potential By Investing.com - Investing.com Canada
Is Kymera Therapeutics Inc. a strong candidate for buy and holdProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Candriam S.C.A. - MarketBeat
How Kymera Therapeutics Inc. stock performs in weak economyIndex Update & Fast Entry and Exit Trade Plans - mfd.ru
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Biotech Innovator with 47.7% Upside Potential - DirectorsTalk Interviews
Certain Warrants of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
Certain Common Stock of Kymera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2026. - marketscreener.com
CEO Moves: Will FATN outperform small cap indexesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - baoquankhu1.vn
Kymera Therapeutics (KYMR) Is Up 7.0% After Advancing Dual Phase 2b Trials for KT-621 - Sahm
Smart Money: What are Kymera Therapeutics Incs earnings expectationsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
KYMR initiates dosing in mid-stage asthma study of lead candidate - MSN
Kymera Therapeutics to Participate in Upcoming February Investor Conferences - Investing News Network
Kymera Therapeutics (KYMR): A Biotech Stock with 54% Potential Upside Amid Innovative Protein Degradation Focus - DirectorsTalk Interviews
(KYMR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings) - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Knights of Columbus Asset Advisors LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Federated Hermes Inc. Makes New Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate - Yahoo Finance
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader By Investing.com - Investing.com South Africa
Kymera begins dosing in phase 2b asthma trial for oral STAT6 degrader - Investing.com India
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Announces First Patient Dosed In Breadth Phase 2B Asthma Clinical Trial Of KT-621, A First-In-Class, Oral Stat6 Degrader - TradingView
Analyst Barclays Raises Price Target for Kymera Therapeutics (KY - GuruFocus
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):